Abstract| Volume 23, ISSUE 10, SUPPLEMENT , S52, October 2017

Risk Stratification with Oral Glucose Tolerance Test and Microalbuminuria in Patients with Chronic Heart Failure -Subanalysis of the SUPPORT Trial-

      Background: Limited data exists for clinical utility of oral glucose tolerance test (OGTT) and microalbuminuria in patients with chronic heart failure (CHF). Methods: We analyzed 554 CHF patients (mean 66 yrs, women 25%, HbA1c 6.4%) from the control arm of the SUPPORT Trial. The primary outcome was a composite of all-cause death, myocardial infraction, stroke, and HF hospitalization for 5 years. For patients without diabetes mellitus (DM), we performed OGTT to detect newly-diagnosed diabetes mellitus (NDDM) and impaired glucose tolerance (IGT). Microalbuminuria was defined as spot urine albumin≥30 mg/L. Finally, we examined 283 DM (known DM 280, NDDM 3, mean 66 yrs, women 22%), 113 IGT (mean 67 yrs, women 30%) and 158 non-diabetic controls (mean 64 yrs, women 27%). Results: In the Cox model, adjusted hazard ratios (HRs) for IGT, DM (known and NDDM) and microalbuminuria were 0.98 (0.60–1.60, P = .93), 1.23 (0.81–1.87, P = .32), and 1.77 (1.24–2.52, P = .002) in the overall population. HRs for IGT with and without microalbuminuria were 0.78 (0.37–1.62, P = .50) and 2.16 (1.10–4.22, P = .025, P for interaction = 0.049) and HRs for DM with and without microalbuminuria were 1.40 (0.79–2.50, P = .25) and 2.05 (1.17–3.59, P = .012, P for interaction = 0.001), respectively. Conclusions: In CHF patients, IGT itself was not a prognostic factor but was associated with poor prognosis when complicated by microalbuminuria, showing clinical utility of combined assessment of OGTT and microalbuminuria.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect